Conference abstract · 21 Oct 2013
Conference abstractPublished 17 Dec 2014
Biosimilars: Opportunities and challenges
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A biosimilar is a successor to a biologic medicine that has lost patent protection or exclusivity. Due to their relative complexity, biosimilars represent a separate regulatory class of medicines to small-molecule generics. Biosimilars are biologics, and are approved via stringently defined regulatory pathways on the basis that they have demonstrated comparability (high similarity) to their reference product. The introduction of biosimilars in the EU has already led to significant savings for patients and payers. With many more such products at various stages of the development pipeline, the number of therapeutic areas catered for by biosimilars will increase steadily over the next decade. The real benefit of biosimilars is the introduction of genuine competition into an area that has historically been unhealthily short of it. Competition not only reduces prices; it also frees up public funds to broaden overall access to healthcare. In addition, it provides a further incentive for the producers of patent-protected medicines to come up with fresh ideas and genuinely original new products ? driving the ?virtuous circle? of innovation. Biosimilar development requires substantial time and investment. A typical biosimilar takes 7-8 years to develop, at a cost of between USD 75 and 250 million, with clinical trials that may involve about 500 patients. That compares to 8-10 years for a new drug application, at a cost of USD 800 million, including up to 1000 patients in clinical trials. For a smallmolecule generic, by comparison, development may be completed in 2-3 years, at a cost of USD 2-3 million.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Biosimilars panel: Opportunities and challenges to be overcome in the near term
Conference abstract · 23 Jun 2023
From biosimilars to affordable copies of biologics; access opportunities, scientific and regulatory challenges and emerging solutions
Conference abstract · 7 Nov 2016
Challenges and opportunities for biosimilar industry in China
Conference abstract · 25 Sep 2014
Production of biosimilars in developing countries: Challenges and opportunities: SEDICO case Study
More from this journal
The newest in Clinical Pharmacology & Biopharmaceutics.
Research article · 27 Jul 2026
Qualitative LC/MS Assessment of Fenfluramine Hydrochloride After Dilution in Purified Water : A Preliminary Study and Case Report
Article · 20 Jul 2026
Population Pharmacology: Precision Dosing for Diverse Patients
Article · 17 Jul 2026
Therapeutic Drug Monitoring: Optimizing Therapy, Minimizing Toxicity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ibrahim A Alsarra”
